WebIMV Stock 12 Months Forecast. C$25.80. ―. Based on 1 Wall Street analysts offering 12 month price targets for IMV in the last 3 months. The average price target is C$25.80 with a high forecast of C$25.80 and a low forecast of C$25.80. The average price target represents a 3482.83% change from the last price of C$0.72. Highest Price Target C ... WebDec 28, 2024 · IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and va
Did you know?
WebFeb 8, 2014 · TSX-V: IMV Immunovaccine is a biotechnology company focused on advancing cancer therapies and infectious disease vaccines based on its patented immune enhancement platform DepoVaxTM Highlights Advance cancer immune therapies designed to maintain patients in remission and improve survival Develop … WebMar 29, 2024 · Get the latest stock price for IMV Inc. (IMV), plus the latest news, recent trades, charting, insider activity, and analyst ratings. ... Visit the TSX ETF Investor Centre …
WebThe TSX overall saw 3,914 price advancers against 1,403 declines and 110 unchanged. During the prior 52 weeks, IMV.TO has traded as high as $17.70 (April 18,2024) and low as $0.62 (March 27,2024). WebFeb 13, 2024 · IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based …
WebAug 4, 2024 · IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies WebIMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2024 Financial and Operational Results. DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 16, …
WebDec 9, 2024 · About IMV Inc. (TSX: IMV) IMV Inc. is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery …
WebMar 31, 2024 · IMV Inc. (“ IMV ” or the “ Company ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel … tarsus lengthWebMar 31, 2024 · DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., (BUSINESS WIRE) -- IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating ... tarsus map locationWebDec 13, 2024 · DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 13, 2024--IMV Inc. (the "Corporation" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of ... tarsus locationWebAug 5, 2024 · In obtaining TSX listing approval, the Company has relied on the “Eligible Interlisted Issuer” exemption from TSX rules under section 602.1 of the TSX Company Manual. Piper Sandler, at IMV’s ... tarsus manor senior housingWebSep 5, 2024 · IMV back at key technical level IMV surged during late trading on 7/23 with post market action taking it to highs of $3 and ultimately settling back around $2.65. … tarsus offpriceWebIMV Inc. Announces Changes to Its Board of Directors. DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., March 27, 2024--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage … tarsus medical log inWebMar 16, 2024 · DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced alongside the release of its fourth quarter and … tarsus mortal shell